Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947685 · ClinicalTrials.gov registry record · Phase 3
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
A Phase 3 study of HER2-positive Breast Cancer and Estrogen Receptor-positive Breast Cancer, sponsored by Alliance Foundation Trials.
- Active
- Registry status
- Phase 3
- Development phase
- 518
- Enrollment target
- 20
- Study locations
NCT02947685: Active Phase 3 study of HER2-positive Breast Cancer and Estrogen Receptor-positive Breast Cancer, sponsored by Alliance Foundation Trials.
NCT02947685 is a Phase 3 study of HER2-positive Breast Cancer and Estrogen Receptor-positive Breast Cancer that is active but no longer recruiting, run by Alliance Foundation Trials. The registered enrollment target is 518 participants, above the 227-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (128% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02947685, a Phase 3 study of HER2-positive Breast Cancer and Estrogen Receptor-positive Breast Cancer, is active but no longer recruiting, sponsored by Alliance Foundation Trials.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 518 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.
Primary Outcome
The time from registration to disease progression or death.
Conditions Studied
Interventions
- DRUG Anastrozole
- DRUG letrozole
- DRUG palbociclib
- DRUG trastuzumab
- DRUG pertuzumab
Study Locations (20)
Florida
- Baycare Healthcare (Morton Plant Mease) - Clearwater
- Memorial Healthcare System - Hollywood
- University of Miami - Miami
- Florida Hospital - Orlando
Illinois
- University of Illinois at Chicago - Chicago
- Ingalls Memorial Hospital - Harvey
Maryland
- University of Maryland - Greenebaum Comprehensive Cancer Center - Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Lowell General Hospital - Lowell
Michigan
- Michigan Cancer Research Consortium (St. Joseph Mercy Hospital - Ann Arbor
- West Michigan Cancer Center - Grand Rapids
Minnesota
- Metro-Minnesota NCI Community Oncology Research Program - Minneapolis
- Mayo Clinic, Rochester, MN - Rochester
California
- UCSF - San Francisco
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2017-06-21 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 3 |
What the registry record for NCT02947685 still lists
NCT02947685 is an interventional study that assigns participants to a tested intervention. The registered 518 participants enrollment target is mid-sized for trials with a published cap, above the 227-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (128% higher).
The record links to 2 conditions, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Anastrozole is the first listed.
NCT02947685 names 20 study sites across 12 states, led by Florida, Illinois, Maryland.
Frequently Asked Questions
What is clinical trial NCT02947685 about?
NCT02947685 is a clinical study titled "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer". The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast ca...
What is the current status of trial NCT02947685?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 518 participants. The study started on 2017-06-21. Estimated completion is 2026-07-31.
What conditions does trial NCT02947685 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer, Estrogen Receptor-positive Breast Cancer.
What interventions are being tested in trial NCT02947685?
The interventions under investigation include: Anastrozole (DRUG), letrozole (DRUG), palbociclib (DRUG), trastuzumab (DRUG), pertuzumab (DRUG).
Who is sponsoring clinical trial NCT02947685?
This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02947685 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02947685's enrollment target sits among peer trials
518 5th of 58 higher than 54 of 58 other HER2-positive Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HER2-positive Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
RECRUITING · Phase 3
-
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
TRUDI: TDXD+Durva in HER2+/Low IBC
RECRUITING · Phase 2
-
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04524871 · 518 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- NCT07112196 · 518 participants · Phase 2
Visugromab in Cachexia International Trial
- NCT05676450 · 517 participants · NA
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI